Journal article
Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials
Abstract
Two phase 3 trials, COMET-1 and COMET-2, have reported that cabozantinib did not significantly extend overall survival (OS) compared to prednisone and prednisone plus mitoxantrone, respectively, in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a retrospective analysis of a combined data set from these trials to identify a benefit in subsets of patients according to prognostic risk factors. ā¦
Authors
Sonpavde GP; Pond GR; Fizazi K; de Bono JS; Basch EM; Scher HI; Smith MR
Journal
European Urology Oncology, Vol. 3, No. 4, pp. 540ā543
Publisher
Elsevier
Publication Date
August 2020
DOI
10.1016/j.euo.2018.11.006
ISSN
2588-9311